All In MedTech

FDA Clearance Tracker · P140015

T:SLIM G4 INSULIN PUMP WITH DEXCOM G4 PLATINUM CGM

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Sep 8, 2015 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Sep 8, 2015

Approved

Time to decision

418 days

Received Jul 17, 2014. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P140015
Device name
T:SLIM G4 INSULIN PUMP WITH DEXCOM G4 PLATINUM CGM
Applicant location
San Diego, CA
Received
Jul 17, 2014
Decided
Sep 8, 2015
Decision
Approved
Supplements
29 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code OYC

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE T:SLIM G4 INSULIN PUMP WITH DEXCOM G4 PLATINUM CGM (¿T:SLIM G4 SYSTEM¿). THIS DEVICE CONSISTS OF THE T:SLIM G4 INSULIN PUMP PAIRED WITH THE DEXCOM G4 PLATINUM SENSOR AND TRANSMITTER.THE T:SLIM G4 INSULIN PUMP IS INTENDED FOR THE SUBCUTANEOUS DELIVERY OF INSULIN, AT SET AND VARIABLE RATES, FOR THE MANAGEMENT OF DIABETES MELLITUS IN PERSONS REQUIRING INSULIN. THE T:SLIM G4 INSULIN PUMP CAN BE USED SOLELY FOR CONTINUOUS INSULIN DELIVERY AND AS PART OF THE T:SLIM G4 SYSTEM TO RECEIVE AND DISPLAY CONTINUOUS GLUCOSE MEASUREMENTS FROM THE DEXCOM G4 PLATINUM SENSOR AND TRANSMITTER. THE T:SLIM G4 SYSTEM ALSO INCLUDES CONTINUOUS GLUCOSE MONITORING (CGM) INDICATED FOR DETECTING TRENDS AND TRACKING PATTERNS IN PERSONS WITH DIABETES FOR USE AS AN ADJUNCTIVE DEVICE TO COMPLEMENT, NOT REPLACE, INFORMATION OBTAINED FROM STANDARD HOME GLUCOSE MONITORING DEVICES. THE T:SLIM G4 SYSTEM AIDS IN THE DETECTION OF EPISODES OF HYPERGLYCEMIA AND HYPOGLYCEMIA, FACILITATING BOTH ACUTE AND LONG-TERM THERAPY ADJUSTMENTS, WHICH MAY MINIMIZE THESE EXCURSIONS. INTERPRETATION OF THE T:SLIM G4 SYSTEM RESULTS SHOULD BE BASED ON THE TRENDS AND PATTERNS SEEN WITH SEVERAL SEQUENTIAL READINGS OVER TIME. THE T:SLIM G4 SYSTEM IS INDICATED FOR USE IN INDIVIDUALS 12 YEARS OF AGE AND GREATER. THE T:SLIM G4 SYSTEM IS INTENDED FOR SINGLE PATIENT USE AND REQUIRES A PRESCRIPTION.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code OYC. The earliest in FDA's data is P130007, decided Nov 25, 2014.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Tandem Diabetes Care, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.